Propanc Biopharma (PPCB) shares surge 166.34% intraday after positive preclinical data release
ByAinvest Wire
Thursday, Aug 27, 2026 10:29 am ET1min read
PPCB--
Propanc Biopharma (PPCB) shares surged 166.34% in intraday trading after the company released positive preclinical data for its drug candidate PRP. The data demonstrated over 90% tumor growth inhibition and more than 2.5 times median survival in pancreatic cancer models. The company also announced a $5 million share repurchase plan and stated it is accelerating toward a Phase 1b clinical trial application.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
LEGAL
Privacy PolicyTerms of UseAIME Terms of UseBrokerage DisclaimerAI Risk DisclosuresEditorial PolicyCONTACT US
Email: support@ainvest.com, editorial@ainvest.com, corrections@ainvest.com, press@ainvest.com, legal@ainvest.com
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet